| pubmed-article:19880657 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19880657 | lifeskim:mentions | umls-concept:C0390423 | lld:lifeskim |
| pubmed-article:19880657 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:19880657 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:19880657 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19880657 | pubmed:dateCreated | 2010-3-3 | lld:pubmed |
| pubmed-article:19880657 | pubmed:abstractText | The development of the first drug-like selective angiotensin II type 2 (AT(2)) receptor agonist (22) derived from the non-selective angiotensin II type 1 (AT( 1)) receptor/AT(2) receptor agonist L-162,313 is presented. Compound 22 with a K(i) value of 0.4 nM for the AT( 2) receptor and a K(i) > 10 microM for the AT(1) receptor induces outgrowth of neurite cells, stimulates p42/p44( mapk), enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats and lowers the mean arterial blood pressure in anaesthetised spontaneously hypertensive rats. Thus, the peptidomimetic 22 exerts a similar biological response as the endogenous peptide angiotensin II after selective activation of the AT(2) receptor. In addition, Compound 22 has a bioavailability of 20-30% after oral administration and a half-life estimated to four hours in the rat. Compound 22 will therefore serve as a valuable research tool enabling studies of the function of the AT(2) receptor in more detail. | lld:pubmed |
| pubmed-article:19880657 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19880657 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880657 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19880657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880657 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19880657 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:19880657 | pubmed:issn | 1752-8976 | lld:pubmed |
| pubmed-article:19880657 | pubmed:author | pubmed-author:AltermanMathi... | lld:pubmed |
| pubmed-article:19880657 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19880657 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:19880657 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19880657 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19880657 | pubmed:pagination | 57-66 | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:meshHeading | pubmed-meshheading:19880657... | lld:pubmed |
| pubmed-article:19880657 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19880657 | pubmed:articleTitle | Development of selective non-peptide angiotensin II type 2 receptor agonists. | lld:pubmed |
| pubmed-article:19880657 | pubmed:affiliation | Department of Medicinal Chemistry, BMC, Uppsala University, Uppsala, Sweden. mathias.alterman@orgfarm.uu.se | lld:pubmed |
| pubmed-article:19880657 | pubmed:publicationType | Journal Article | lld:pubmed |
